An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance ...

Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune <a target=_blank h ...

Celltrion's ustekinumab biosimilar is now available in France, Italy, Spain, Britain and Germany after securing European ...

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

On December 17, 2024, the Competition Tribunal (the Tribunal) issued reasons for its decision to dismiss an application for leave to bring a ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Accord Healthcare Limited (Accord) announces that the European Commission (EC) has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar of Stelara® (ustekinumab), ...

Celltrion Inc.'s autoimmune disease treatment, SteQeyma, has been launched in five major European nations, the Korean company ...

SteQeyma, an ustekinumab biosimilar treatment for multiple chronic inflammatory diseases, was released in France on Monday, following its launch in Italy and Spain earlier this month, according to ...